Not a direct response to your challenge, Mita, but a scenario of...

Not a direct response to your challenge, Mita, but a scenario of my own. This one is less forward looking and is based on current data.
Last year ACR paid an 8c final dividend.
Axiron net sales for last FY (taken from Eli Lilly data in ACR's last quarterly update)
Q3 2012 16.0
Q4 2012 23.9
Q1 2013 37.1
Q2 2013 47.1
Total 124.1
Sales for this year
Q3 2013 40.6
Q4 2013 53.9
Q1 2014 39.5
Q2 2014 Still in play
Total 134

So, even if there are ZERO sales for this final quarter, it's still an 8% increase on all of last year. USD has been stronger for most of this year too which boosts the AUD received.
Is it right to conclude that they should be able to maintain the 8c? that's a pretty good return on an 86c stock. Tax-free as well.